ORIGINAL ARTICLE

A comprehensive multimodal pain treatment reduces opioid consumption after multilevel spine surgery

Ole Mathiesen · Benny Dahl · Berit A. Thomsen · Birgitte Kitter · Nan Sonne · Jørgen B. Dahl · Henrik Kehlet

Received: 2 November 2012/Revised: 5 April 2013/Accepted: 7 May 2013/Published online: 17 May 2013 © Springer-Verlag Berlin Heidelberg 2013

Abstract

Purpose Major spine surgery with multilevel instrumentation is followed by large amount of opioid consumption, significant pain and difficult mobilization in a population of predominantly chronic pain patients. This case–control study investigated if a standardized comprehensive pain and postoperative nausea and vomiting (PONV) treatment protocol would improve pain treatment in this population. *Methods* A new regimen with acetaminophen, NSAIDs, gabapentin, S-ketamine, dexamethasone, ondansetron and epidural local anesthetic infusion or patient controlled analgesia with morphine, was introduced in a post-intervention group of 41 consecutive patients undergoing multilevel (median 10) instrumented spinal fusions and compared with 44 patients in a pre-intervention group. *Results* Compared to patients in the pre-intervention

group, patients treated according to the new protocol

O. Mathiesen (⊠) · B. A. Thomsen · B. Kitter · N. Sonne Section of Acute Pain Management and Palliative Medicine, Department of Anesthesia 4231, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark e-mail: olemat@dadlnet.dk

B. Dahl

Spine Unit, Department of Orthopaedic Surgery 3191, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

J. B. Dahl

Department of Anesthesia 4231, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

H. Kehlet

Section for Surgical Pathophysiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark consumed less opioid on postoperative day (POD) 1 (P = 0.024) and 2 (P = 0.048), they were mobilized earlier from bed (P = 0.003) and ambulation was earlier both with and without a walking frame (P = 0.027 and P = 0.027, respectively). Finally, patients following the new protocol experienced low intensities of nausea, sedation and dizziness on POD 1–6.

Conclusions In this study of patients scheduled for multilevel spine surgery, it was demonstrated that compared to a historic group of patients receiving usual care, a comprehensive and standardized multimodal pain and PONV protocol significantly reduced opioid consumption, improved postoperative mobilization and presented concomitant low levels of nausea, sedation and dizziness.

Keywords Major spine surgery · Multimodal pain treatment · Opioid consumption · Mobilization

Introduction

The frequency of spinal surgery has increased during the last decade, especially in patients aged 65 years and older [1, 2]. This includes multilevel instrumentation which is often associated with severe pain and consumption of large amounts of opioids thereby hindering postoperative mobilization and rehabilitation [3, 4]. Also, patients undergoing major spine surgery often suffer from pre-operative chronic pain, further challenging postoperative pain treatment [5, 6].

Postoperative pain is the result of activation of different pain mechanisms, including nociceptive, neuropathic and inflammatory pains. Likewise, peripheral and central sensitization further contributes to the development of hyperalgesia with increased pain as a result. Therefore, a balanced analgesic treatment addressing the different mechanisms represents a logical therapeutic approach [7]. A reduction in opioid consumption and opioid related side-effects is of special concern in this approach [8, 9].

A number of studies have focused on pain treatment in spine surgery, but most studies have focused on primary degenerative conditions in the lumbar spine treated with discectomy, decompression and lumbosacral fusion [10, 11]. Since an increased number of major spinal procedures, including revision surgery can be anticipated, we found it of relevance to assess a multimodal pain treatment strategy in patients undergoing surgery requiring instrumentation on >3 levels.

Our hypothesis was that a comprehensive pain and postoperative nausea and vomiting (PONV) treatment regimen would reduce opioid consumption and improve postoperative mobilization, while maintaining low levels of side-effects. The aim of this study was to assess the effect of such a standardized regimen and to compare opioid consumption and postoperative mobilization with those of a pre-intervention control group.

Materials and methods

The study was carried out at the Spine Unit, Department of Orthopaedic Surgery, Rigshospitalet, Copenhagen University Hospital, Denmark. Adult patients scheduled for elective posterior instrumented fusion on >3 levels for non-malignant and non-infectious conditions of the spine were included in the study.

Design

A new standardized pain and PONV treatment protocol was introduced from 1 January 2011. Consecutive patients receiving the standardized treatment protocol were monitored prospectively to document treatment effects. No randomization was done. According to The local Regional Ethics Committee guidelines in Denmark, no approval was needed. The study was approved by the Danish data protection agency (2008-41-2128).

Patients

Pre-intervention group

Data from 44 comparable patients operated from October 2009 through November 2010 were collected based on review of the medical records and electronic patient's medicine (EPM) files. Thus, a total of 44 patients undergoing similar procedures were included.

Post-intervention group

Data from 41 consecutive patients who received the new treatment protocol were registered prospectively from January 2011 to June 2011.

Intervention

All patients had general anesthesia with propofol and remifentanil. Controlled hypotension was employed and 2 g of tranexamic acid was administered intravenously immediately prior to the surgical procedure. All patients underwent posterior instrumented fusion with pedicle screws on >3 levels with a midline incision and subperiosteal exposure of the relevant levels. The primary indications for surgery were adult deformity or primary degenerative conditions.

Postoperatively, patients were extubated and transferred to the postanesthesia care unit (PACU).

No modification of the standard mobilization program was introduced in the study period compared to the period for the pre-intervention data. Patients were trained daily by a physiotherapist except at weekends during which the patients were mobilized with help of the ward staff. The criteria for discharge were mobilization from bed to standing position, independent personal hygiene, and independent or assisted stair climb corresponding to one floor [12].

A detailed description of the treatments in the pre- and post-intervention groups is provided in Table 1. The new standardized protocol covered the handling of the patient from before surgery until discharge and was intended for all patients. However, patients with regular opioid consumption >100 mg morphine (eq.)/day, had the following adjustments: IV morphine dose before the end of surgery was 0.4 mg/kg, S-ketamine 0.03 mg/kg/h was continued for 72 h; prolonged release morphine at the discontinuation of either the epidural or the PCA treatment was substituted by increasing the patient's usual opioid dosing with 50 %/day.

Endpoints

The primary endpoint was opioid consumption (oral morphine eq.) on postoperative days (POD) 1–6. Secondary endpoints were number of days until the patients could be mobilized from bed and until the patients were able to walk with and without a walking frame, numeric rating scale (NRS) pain score (0 = no pain and 10 = worst pain imaginable) at rest and during mobilization on POD 1–6, levels of side-effects (nausea, sedation and dizziness) on POD 1–6 and postoperative length of stay (LOS) at the PACU and at the surgical department.

| ADA at the discretion of the arcsitist, OR roal, PCA Portendication Usual opioid medication Scalanoption OR 2 g (sustained release) ADA at the discretion of the arcsitist, OR roal, PCA Remiferitani and propor Remiferitani and propor Remiferitani and propor ADA at the discretion of the arcsitist, OR roal, PCA Reduction of the arcsition Usual opioid medication Usual opioid medication ADA at the discretion of the arcsitist, OR roal, PCA PoNV PoNV PoNV arcsition ADA at the discretion of the arcsitist, OR roal, PCA Epidural bolus of bupivacaine 5 ml 2.5 mg/ml PONV PoNV prophylaxis: ADA Morphine (ADA) Retamine IV 0.3 mg/kg supplied 45 min before the end of surgery. Postoperative Epidural, placed at the discretion of the arcsitist and propore OR 1 g x 4 Epidural catheter (tip at the middle of the surgical field), bolus: bupivacaine 0.5 mg/ml 10 ml If epidural information of the arcsitist and proper OR 1 g x 4 PoNV prophylaxis: ADA Ondansetron IV 4 mg Postoperative Usual opioid medication Usual opioid medication Usual opioid medication ADA at the discretion of the arcsitistist Feidural for up to 72 h or PCA Repidural infusion and propore OR 1 g x 4 ADD, at the discretion of the arcsitististististign Relaxes morphine 2 mg/ml Morphine CR or IV as needed | Table 1 Pre- and post-intervention treatment | | Pre-intervention protocol | Post-intervention protocol |
|--|---|---------------|------------------------------|---|
| ADA at the discretion of the ansektediat Regination of the surgeory of the surge | | Premedication | Usual opioid medication | Usual opioid medication |
| ADA at the discretion of the ansektiviti, OR ong heat, CR at the discretion of the ansektiviti, OR ong heat, CR at the discretion of the ansektiviti, OR ong heat, CR at the discretion of the ansektiviti, CR ong heat, PCA morphine CR or V2 heat, CR at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon, bolus at the discretion of the ansektivities of the surgeon of the surgeon, bolus at the discretion of the ansektive the the the the the the the the the th | | | No standardized treatment | Acetaminophen OR 2 g (sustained release) |
| General anesthesia Remifentanil and propofol Fentanyl (ADA) Remifentanil and propofol Dexamethasone IV 24 mg Selectamine IV 0.5 mg/kg + 0.3 mg/kg/h until 45 min before the end of surgery Selectamine IV 0.5 mg/kg supplied 45 min before the end of surgery Morphine (ADA) Morphine IV 0.3 mg/kg supplied 45 min before the end of surgery Epidural, placed at the discretion of the surgeon, bolus at the discretion of the surgeon, bolus at the discretion of the anesthetist Epidural, claced at the discretion of the anesthetist PONV prophylaxis: ADA Ondansetron IV 4 mg Usual opioid medication Usual opioid medication Acetaminophen OR 1 g × 4 Acetaminophen OR 1 g × 4 Houprofon OR 400 mg × 4 until discharge Gabapentin OR 400 mg × 4 until discharge Gabapentin OR 400 mg × 4 until discharge Gabapentin OR 400 mg × 2 until discharge Gabapentin OR 10 mg × 4 Additional pain Epidural bolus of bupivacaine 2.5 mg/ml Sustained release morphine 20 mg × 2 after end of EPI or PCA Morphine OR or IV as needed Morphine OR or IV as needed Morphine 0R or IV as needed PONV treatment Fpidural bolus of bupi | | | | Celecoxib OR 400 mg |
| ADA at the discretion of the ansektivits, OR oral, PCA Additional Finanyl (ADA) Dexamethasone IV 24 mg Sketamine IV 0.5 mg/kg + 0.3 mg/kg/h until 45 min before the end of surgery Morphine (ADA) Morphine IV 0.5 mg/kg + 0.3 mg/kg/h until 45 min before the end of surgery Morphine (ADA) Morphine IV 0.5 mg/kg + 0.3 mg/kg supplied 45 min before the end of surgery Epidural, placed at the discretion of the surgical field), bolus: bupivacaine 0.5 mg/ml 10 ml If epidural catheter (tip at the middle of the surgical discretion of the ansethetist) Epidural catheter (tip at the middle of the surgical field), bolus: bupivacaine 0.5 mg/ml 10 ml If epidural not possible, local infiltration analgesia 40 ml with bupivacaine 0.5 mg/ml placed subfacially PONV prophylaxis: ADA Ondansetron IV 4 mg Postoperative analgesia Acetaminophen OR 1 g × 4 Acetaminophen OR 1 g × 4 Buprofen OR 400 mg × 4 until discharge Gabapentin OR 400 + 1,000 mg for 5 days Epidural for up to 72 h or PCA Epidural for up to 72 h or PCA Buparbine for 48 h Opioid ADA If epidural infusion was not possible, PCA morphine (folus 2 mg, lockout 15 min, for 48 h) background infusion 1 mg/h during the first 24 h Sustained release morphine 2 mg × 2 after end of EPI or PCA Morphine OR or IV as needed ADA at the discretion of the ansektive of PONV treatment Morphine OR or IV as needed Morphine OR or IV as needed PONV potpertaive n | | | | Gabapentin OR 900 mg |
| ADA at the discretion of the ansetterist, OR of the stretistic, OR oral, PCA Additional pain Epidural bolus of bupivacaine 2,5 mg/mg + 0,3 mg/kg/h until 45 min before the end of surgery Sketamine IV 0.5 mg/kg + 0.3 mg/kg/h until 45 min before the end of surgery Sketamine IV 0.5 mg/kg + 0.3 mg/kg/h until 45 min before the end of surgery Big Epidural, placed at the discretion of the surgeon, bolus at the discretion of the anesthetist. Epidural catheter (tip at the middle of the surgical field), bolus: bupivacaine 0.5 mg/ml 10 ml Postoperative analgesia PONV prophylaxis: ADA Ondansetron IV 4 mg Postoperative analgesia Usual opioid medication Usual opioid medication Acetaminophen OR 1 g × 4 Houprofen OR 10 mg × 4 until discharge Gabapentin OR 400 + 1,000 mg for 5 days Epidural for up to 72 h or PCA morphine for 48 h Dipioid ADA If epidural bupivacaine 2.5 mg/ml with 50 µg/ml of morphine 5-8 ml/h for 96 h Opioid ADA Epidural bolus of bupivacaine for 9CA Bipdural bolus of bupivacaine for 9CA Morphine as needed PONV PONV Transpine Sing 12.5 mg/ml Morphine con rule as needed PONV PONV PONV To second Morphine Con rule as needed PONV PONV PONV To second Morphine Con rule as needed Dipotral bolus o | | General | Remifentanil and propofol | Remifentanil and propofol |
| ADA at the discretion of the ansthetist, OR ond1, PCA Additional pain Epidural bolus of bupivacaine pain 5 min before the end of surgery 45 min before the end of surgery ADA at the discretion of the ansthetist, OR ond1, PCA painter to controlled analgesia Morphine (ADA) Morphine (V 0.3 mg/kg supplied 45 min before the end of surgery Postoperative analgesia Epidural, placed at the discretion of the anesthetist Epidural catheter (tip at the middle of the surgical field), bolus: bupivacaine 0.5 mg/ml 10 ml If epidural catheter (tip at the middle of the surgical field), bolus: bupivacaine 0.5 mg/ml placed subfacially Postoperative analgesia PONV prophylaxis: ADA Ondansetron IV 4 mg Usual opioid medication Acetaminophen OR 1 g × 4 Ibuprofen OR 400 mg × 4 until discharge Gabapentin OR 400 mg × 4 until discharge Gabapentin OR 400 mg × 4 until discharge Dipidi ADA Epidural for up to 72 h or PCA morphine for 48 h Epidural bupivacaine 2.5 mg/ml with 50 µg/ml of morphine 5-8 ml/h for 96 h Sustained release morphine 20 mg × 2 after end of EPI or PCA ADA at the discretion of the anstetisti, OR or I, PCA patient controlled analgesia PONV treatment Morphine OR or IV as needed Morphine OR or IV as needed PONV treatment PONN treatment Ondansetron Morphine OR or IV as needed Morphine OR or IV as needed PONV treatment | | anesthesia | Fentanyl (ADA) | Dexamethasone IV 24 mg |
| ADA at the discretion of the anethetist, OR oral, PCAFejdural bolus of bupivacaine to many patient controlled analgesia, PONV prostoperative and the discretion of the anesthetistend of surgeryend of surgeryADA at the discretion of the anethetist, OR oral, PCA patient controlled analgesia, PONV PONV treatmentEpidural, placed at the discretion of the surgeon, bolus at the discretion of the anesthetistEpidural catheter (tip at the middle of the surgical field), bolus: bupivacaine 0.5 mg/ml 10 ml If epidural not possible, local infiltration analgesia 40 ml with bupivacaine 2.5 mg/ml placed subfaciallyPostoperative analgesiaPonv analgesiaOndansetron IV 4 mg Usual opioid medication Acetaminophen OR 1 g × 4Ondansetron IV 4 mg Usual opioid medication Acetaminophen OR 1 g × 4Postoperative analgesiaEpidural for up to 72 h or PCA morphine for 48 h Opioid ADAEpidural for up to 72 h or PCA morphine 5-8 ml/h for 96 hAdditional painEpidural bolus of bupivacaine 5 ml 2.5 mg/mlEpidural bolus of bupivacaine 2.5 mg/ml with 50 µg/ml of morphine 5-8 ml/h for 96 hADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV treatmentPONV treatmentMorphine OR or IV as needed OndansetronADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV treatmentPONV treatmentMorphine OR or IV as needed OndansetronADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV treatmentPONV treatmentMorphine OR or IV as needed OndansetronADA at the discretion of t | | | | |
| ADA at the discretion of the ansthetist, OR oral, PCA point controlled analgesia, PONV postoperative nausea andof the surgeon, bolus at the discretion of the anesthetistfield), bolus: bupivacaine 0.5 mg/ml 10 mlADA at the discretion of the ansthetist, OR oral, PCA point controlled analgesia, PONVPonv ponv ponv postoperative analgesiaPonv prophylaxis: ADAField), bolus: bupivacaine 0.5 mg/ml 10 ml If epidural not possible, local infiltration analgesia 40 ml with bupivacaine 2.5 mg/ml placed subfaciallyPostoperative analgesiaPonv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv treatmentPonv ponv ponv ponv ponvPonv ponv ponv ponv ponvPonv ponv ponv ponv ponv ponv ponv ponv ponv ponvPonv ponv ponv ponv ponv ponv ponv ponvPonv ponv ponv ponv ponv ponv ponv ponv ponv ponv ponv ponv ponv ponv ponvPonv ponv< | | | Morphine (ADA) | |
| ADA at he discretion of the anesthetist, OR oral, PCAAdditional painEpidural bolus of bupivacaine postoperative analgesiaEpidural holus of bupivacaine subfaciallyPostoperative subfaciallyADA at he discretion of the anesthetist, OR oral, PCAAdditional patient controlled analgesia, PONV postoperative nausea andEpidural bolus of bupivacaine propride live analgesiaEpidural bolus of bupivacaine propride live analgesiaEpidural bolus of bupivacaine propride live analgesiaEpidural bolus of bupivacaine propride live analgesiaEpidural bolus of bupivacaine propride live propride live propride live propride live propride live patient controlled analgesia, PONV postoperative nausea andEpidural bolus of live propride live live propride live propride live propride live propride live propride live propride live propride live live live live propride live propride live <br< td=""><td rowspan="3"></td><td rowspan="2">of the surgeon, bolus at the</td><td></td></br<> | | | of the surgeon, bolus at the | |
| Postoperative analgesiaUsual opioid medication Acetaminophen OR 1 g × 4Usual opioid medication Acetaminophen OR 1 g × 4Acetaminophen OR 1 g × 4Ibuprofen OR 400 + 1,000 mg for 5 daysEpidural for up to 72 h or PCA morphine for 48 hEpidural for up to 72 h or PCA morphine for 48 hOpioid ADAOpioid ADAAdditional painEpidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andEpidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andEpidural bolus of bupivacaine 5 ml 2.5 mg/mlMorphine OR or IV as needed OndansetronADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV treatmentPONV treatmentMorphine OR or IV as needed OndansetronMorphine OR or IV as needed Ondansetron IV 1 mg Droperidol IV 0.625 mg Dexamethasone IV 8 mg | | | | 40 ml with bupivacaine 2.5 mg/ml placed |
| analgesiaAcetaminophen OR 1 g × 4Acetaminophen OR 1 g × 4Acetaminophen OR 1 g × 4Ibuprofen OR 400 mg × 4 until discharge Gabapentin OR 400 + 1,000 mg for 5 daysEpidural for up to 72 h or PCA morphine for 48 hEpidural for up to 72 h or PCA morphine for 48 hOpioid ADAIf epidural infusion was not possible, PCA morphine (bolus 2 mg, lockout 15 min, for 48 h) background infusion 1 mg/h during the first 24 hAdditional painEpidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andEpidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA potent controlled analgesia, PONV treatmentPONV treatmentEpidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA postoperative nausea andPONV treatmentPONV treatmentPONV treatmentMorphine OR or IV as needed OndansetronADA at the discretion of the anesthetist, OR oral, PCA postoperative nausea andPONV treatmentEpidural bolus of bupivacaine 5 ml 2.5 mg/mlMorphine OR or IV as needed Droperidol IV 0.625 mg Droperidol IV 0.625 mg Droperidol IV 8 mg | | | PONV prophylaxis: ADA | Ondansetron IV 4 mg |
| ADA at the discretion of the anesthetist, OR oral, PCAAdditional patient controlled analgesia, PONV postoperative nausea andEpidural for up to 72 h or PCA morphine for 48 h Opioid ADAAccuminopich OR 1 g × 4 Ibuprofen OR 400 mg × 4 until discharge Gabapentin OR 400 + 1,000 mg for 5 days Epidural for up to 72 h or PCA morphine for 48 h Opioid ADAEpidural for up to 72 h or PCA morphine 5 -8 ml/h for 96 hIf epidural infusion was not possible, PCA morphine (bolus 2 mg, lockout 15 min, for 48 h) background infusion 1 mg/h during the first 24 h Sustained release morphine 20 mg × 2 after end of Epidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andAdditional PONV treatmentEpidural bolus of bupivacaine 5 ml 2.5 mg/mlMorphine OR or IV as needed OndansetronADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andPONV treatmentMorphine OR or IV as needed OndansetronMorphine OR or IV as mg | | 1 | Usual opioid medication | Usual opioid medication |
| ADA at the discretion of the anesthetist, OR oral, PCA ptient controlled analgesia, PONV postoperative nausea andEpidural for up to 72 h or PCA morphine for 48 hGabapentin OR 400 + 1,000 mg for 5 days Epidural bupivacaine 2.5 mg/ml with 50 µg/ml of morphine 5-8 ml/h for 96 hADA at the discretion of the anesthetist, OR oral, PCA PONV postoperative nausea andAdditional PONV treatmentEpidural for up to 72 h or PCA morphine for 48 hIf epidural bupivacaine 2.5 mg/ml with 50 µg/ml of morphine 5-8 ml/h for 96 hADA at the discretion of the anesthetist, OR oral, PCA PONV postoperative nausea andAdditional PONV treatmentEpidural bolus of bupivacaine 5 ml 2.5 mg/mlEpidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA PONV postoperative nausea andPONV treatmentMorphine OR or IV as needed OndansetronMorphine OR or IV as needed Droperidol IV 0.625 mg Dexamethasone IV 8 mg | | | Acetaminophen OR 1 g × 4 | Acetaminophen OR 1 g \times 4 |
| ADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andEpidural for up to 72 h or PCA morphine for 48 hEpidural bupivacaine 2.5 mg/ml with 50 µg/ml of morphine 5–8 ml/h for 96 hADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andEpidural for up to 72 h or PCA morphine for 48 hEpidural bupivacaine 5 ml 2.5 mg/mlEpidural bupivacaine 5 ml 2.5 mg/ml with 50 µg/ml of morphine 5–8 ml/h for 96 hADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andEpidural bolus of bupivacaine 5 ml 2.5 mg/mlEpidural bolus of bupivacaine 5 ml 2.5 mg/mlEpidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andPONV treatmentMorphine OR or IV as needed OndansetronMorphine OR or IV as needed Ondansetron IV 1 mg Droperidol IV 0.625 mg Droperidol IV 0.625 mg Droperidol IV 0.825 mg | | | | Ibuprofen OR 400 mg \times 4 until discharge |
| morphine for 48 hmorphine 5–8 ml/h for 96 hOpioid ADAIf epidural infusion was not possible, PCA morphine (bolus 2 mg, lockout 15 min, for 48 h) background infusion 1 mg/h during the first 24 hSustained release morphine 20 mg × 2 after end of EPI or PCAAdditional painEpidural bolus of bupivacaine 5 ml 2.5 mg/mlADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andEpidural bolus of rIV as needed OndansetronADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andPONV treatmentMorphine OR or IV as needed OndansetronADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea andPONV treatmentMorphine OR or IV as needed OndansetronMorphine OR or IV 1 mg Droperidol IV 0.625 mg Dexamethasone IV 8 mg | | | | Gabapentin OR $400 + 1,000$ mg for 5 days |
| ADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea and Morphine OR or IV as needed Morphine OR or IV as needed Morphine CR or IV as needed Morphine OR or IV as needed Morphine OR or IV as needed Droperidol IV 0.625 mg Droperidol IV 0.625 mg Droperidol IV 0.625 mg Dexamethasone IV 8 mg Dexamethasone IV 8 mg | | | 1 1 | |
| ADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea and Epidural bolus of bupivacaine 5 ml 2.5 mg/ml Morphine OR or IV as needed Epidural bolus of bupivacaine 5 ml 2.5 mg/ml Morphine OR or IV as needed Morphine OR or IV as needed Double of the anesthetist, OR oral, PCA PONV treatment Ondansetron Ondansetron IV 1 mg Droperidol IV 0.625 mg Droperidol IV 0.625 mg Dexamethasone IV 8 mg | | | Opioid ADA | (bolus 2 mg, lockout 15 min, for 48 h) background |
| Additional pain Epidural bolus of bupivacaine 5 ml 2.5 mg/ml Epidural bolus of bupivacaine 5 ml 2.5 mg/ml ADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea and PONV treatment Morphine OR or IV as needed Morphine OR or IV as needed Down postoperative nausea and PONV Droperidol IV 0.625 mg Dexamethasone IV 8 mg | | | | |
| ADA at the discretion of the anesthetist, OR oral, PCA patient controlled analgesia, PONV postoperative nausea and Morphine OR or IV as needed Morphine OR or IV as needed Morphine OR or IV as needed Morphine OR or IV as needed Morphine OR or IV as needed Droperidol IV 0.625 mg Dexamethasone IV 8 mg | | | | Morphine as needed |
| ADA at the discretion of the anesthetist, OR oral, PCA PONV Ondansetron Ondansetron IV 1 mg patient controlled analgesia, treatment Droperidol IV 0.625 mg PONV postoperative nausea and Dexamethasone IV 8 mg | | | | Epidural bolus of bupivacaine 5 ml 2.5 mg/ml |
| anesthetist, OR oral, PCAPONVOndansetronOndansetronpatient controlled analgesia,treatmentDroperidol IV 0.625 mgPONV postoperative nausea andDexamethasone IV 8 mg | | | Morphine OR or IV as needed | Morphine OR or IV as needed |
| patient controlled analgesia,treatmentDroperidol IV 0.625 mgPONV postoperative nausea andDexamethasone IV 8 mg | | | Ondansetron | Ondansetron IV 1 mg |
| | | | | Droperidol IV 0.625 mg |
| | | | | Dexamethasone IV 8 mg |

Data collection

Data for patients in the pre- and post-intervention treatment protocol were tracked and collected from the anesthesia, the PACU, and the patient and nurse records, as well as the EPM files. All patients answered a pre-operative Short Form (36) Health Survey (SF-36) [13] questionnaire assessing health-related quality of life. Data of mobilization were collected from the physiotherapists' record. Furthermore, data from patients in the post-intervention protocol were supplied with a scheduled assessment on POD 1–6 at 9 AM. Patients were interviewed by one of the authors about their NRS pain (0-10) at rest and during mobilization (from side to side in bed) and about the intensity (none, mild, moderate, severe) of nausea, dizziness and sedation for the previous 24 h.

For statistical comparisons, the oral morphine equivalent dose was calculated based on the following oral ratios: oxycodone (2:1), ketobemidone (2:1), tramadol (1:10), fentanyl (100:1) and methadone (5:1). For IV opioid consumption a 1:1 ratio was used for morphine, oxycodone and ketobemidone. Comparison of opioid consumption on POD 1 and 2 was only done in patients without a PCA device [group pre-intervention: n = 31 (POD 1) and n = 33 (POD 2); group post-intervention: n = 27 (POD 1 and 2)] because of lack of data regarding infusion.

Patients with a dura lesion requiring bed rest for more than 24 h postoperatively are not included in mobilization data (group pre-intervention: n = 1; group post-intervention: n = 3). Furthermore, patients in whom no data about walking ability were available at discharge or transferral to another hospital were considered able to walk without a

walking frame for either the day of discharge or for 1 day after the day of transfer to another hospital.

Statistical methods

Data are presented as medians with interquartile range (IQR) or minimum/maximum. P < 0.05 was considered statistically significant. The Mann–Whitney U test for unpaired data was used to compare differences between groups for morphine consumption on POD 1–6, levels of mobilization and LOS at the PACU and the surgical department. Bonferroni correction for multiple comparisons was performed on data of morphine consumption and mobilization at the surgical department. Numerical values were attributed to verbal scores of pain, nausea, sedation, and dizziness (none = 1; mild = 2; moderate = 3 and severe = 4). Categorical data were compared with Fischer's exact test. Calculations were performed using SPSS 17 for Windows (SPSS, Chicago, IL). The authors did all statistical analysis.

Results

From January 2011 to June 2011, 41 consecutive patients receiving the post-intervention protocol were included in the study and were compared to a pre-intervention group of 44 patients. The baseline demographics and clinical characteristics were similar between groups (Table 2). Also, no significant differences in SF-36 scores between the two groups could be demonstrated. In all patients, the indication for surgery was spinal deformity or a degenerative condition requiring posterior instrumentation on >3 levels.

Opioid consumption and pain on POD 1-6

Morphine administration (oral eq.) was significantly reduced with the post-intervention protocol on POD 1 [110 (55–180) vs. 15 (0–120) mg)] (P = 0.024) and on POD 2 [100 (40–149) vs. 30 (0–120) mg)] (P = 0.048), but not on POD 3–6 (Fig. 1).

Mobilization

Mobilization was significantly improved for patients in the post- compared to the pre-intervention group. The mobilization ability of patients, i.e., from bed (median and IQR): [1 (1–1) vs. 1 (1–2.5) days (P = 0.003)], walking with [2 (1–2.5) vs. 3 (1–5) days (P = 0.027)] and without a walking frame [5 (3–7) vs. 7 (5–9.3) days (P = 0.027)] is demonstrated in Fig. 2a–c.

Table 2 Patient characteristics and perioperative data

| Variable | Pre-intervention $(N = 44)$ | Post-intervention $(N = 41)$ | P value |
|---|-----------------------------|------------------------------|---------|
| Age (years) | 63 (18-85) | 59 (17-83) | 0.22 |
| Gender (female vs. male) | 30 vs. 14 | 27 vs. 14 | 1.0 |
| Height (cm) | 166 (149–192) | 171 (155–190) | 0.11 |
| Weight (kg) | 70 (45–129) | 69 (54–112) | 0.90 |
| Pre-operative daily opioid consumption (<i>n</i>) | 23 | 26 | 0.38 |
| Duration of surgery (min) | 288 (138-406) | 275 (114–491) | 0.26 |
| Number of instrumented spinal levels | 9.5 (4–15) | 10 (4–16) | 0.61 |
| Surgical approach | | | |
| Posterior | 44 | 41 | 1.00 |
| Thoracic | 1 | 0 | 1.00 |
| Smith–Peterson osteotomy | 5 | 1 | 0.20 |
| Pedicle subtraction osteotomy | 9 | 9 | 1.00 |
| Iliac instrumentation | 17 | 28 | 0.009 |
| Postoperative length of stay before discharge | 9 (6.3–10.8) | 7 (5–10) | 0.39 |

Values are median (interquartile range) or number of patients

Pain scores and side-effects

Due to inconsistency of pain and side-effect data in the pre-intervention group, comparison between groups was not possible. Instead, data are presented for the post-intervention group only based upon morning assessments on POD 1–6. Median NRS pain at rest was 3–5, and during mobilization 5–7 for the first 6 postoperative days (Table 3).

The median intensity of nausea for the first 6 PODs ranges from 0 to 1 (Table 3). PONV treatment was administered in 17-21 % of the patients on POD 1–6. In general, the reported median levels of sedation and dizziness were 1 on POD 1–6, corresponding to a verbal level of mild sedation or dizziness (Table 3).

There was no significant difference in the 1-year revision rate because of pseudarthrosis in the two groups. Two patients in the pre-intervention group were re-operated because of postoperative hematoma; none in the postintervention group.

There were no postoperative infections in neither of the groups assessed by prolonged perioperative antibiotics and/ or revision surgery due to infection.




Fig. 1 Box plot showing oral morphine (eq.) consumption on postoperative days (POD) 1–6. Data for POD 1 + 2 are without patients treated with patient controlled analgesia (PCA) devices. Plots demonstrate medians and IQR. Whiskers show 5 and 95 % percentiles. The 24-h morphine consumption was significantly reduced on postoperative day 1 (P = 0.024) and 2 (P = 0.048) in the post-intervention group receiving the new multimodal pain treatment protocol

All patients had a bladder catheter for the duration of the epidural pain treatment, and no patients had urinary retention after removal of the bladder catheter.

Length of stay at the PACU and surgical department

LOS at the PACU was significantly reduced for the postvs. pre-intervention group: 270 (173–353) vs. 345 (240–480) min (P = 0.007).

In the pre-intervention group, 64 % of the patients were discharged to home vs. 66 % of the patients in the post-intervention group. The remaining patients were transferred to another hospital for convalescence. LOS was not significantly different between groups: 9 (IQR 6.3–10.8) (pre-intervention group) vs. 7 (IQR 5–10) (post-intervention group) days (P = 0.39) (Table 2).

Discussion

In this study, we have reported the effect of a comprehensive multimodal analgesic and anti-emetic treatment protocol in a population of patients undergoing major spine surgery and compared to those of a historic group receiving usual care. Compared to a historic pre-intervention group, postoperative morphine consumption was reduced together with improved mobilization and with concomitant low intensities of nausea, sedation and dizziness for POD 1–6.

To our knowledge, the present study is the first to report a possible effect on pain treatment and mobilization from a




Fig. 2 a–c Mobilization ability as the percentage of patients achieving a fixed endpoint: mobilization from bed, walking with a walking frame and walking without a walking frame. The ability to be mobilized from bed (P = 0.003), as well as walking with (P = 0.027) and without (P = 0.027) the help of a walking frame was significantly improved in the post-intervention group receiving the new multimodal pain treatment protocol

| POD VAS pain at rest | | VAS pain during mobilization | Nausea (0-3) | Sedation (0–3) | Dizziness (0-3) |
|----------------------|-------------|------------------------------|--------------|----------------|-----------------|
| 1 | 3 (0.5–6.5) | 7 (5–10) | 0 (0–1) | 1 (0–2) | 0 (0-0) |
| 2 | 3 (0-6) | 5 (2.5–7) | 0 (0–1) | 1 (0–3) | 1 (0-2) |
| 3 | 4 (1–7) | 6 (3.5–8.5) | 0 (0–1) | 1 (0-2) | 1 (0–3) |
| 4 | 5 (2.8–7.3) | 6 (4–8) | 1 (0–1.5) | 1 (0.5–2) | 1 (0–1.5) |
| 5 | 4 (1–7) | 6 (3–8) | 0.5 (0-2) | 1 (0-2) | 1 (0-2) |
| 6 | 5 (2.5–7.5) | 6 (4.5–8) | 0 (0–2) | 0 (0–1.5) | 1 (0–1.5) |

Table 3 Postoperative pain scores and levels of side-effects at 9 AM in the post-intervention group

Values are median and interquartile range (IQR), postoperative day (POD), visual analog scale (VAS), range: 0 = no pain, 10 = worst pain imaginable; levels of side-effects: none = 0, slight = 1, moderate = 2, severe = 3

multimodal pain treatment strategy involving acetaminophen, NSAIDs, gabapentin, dexamethasone, S-ketamine and epidural pain treatment or PCA morphine in patients undergoing major spine surgery. There is no consensus on the term "major spine surgery" and it is sometimes used synonymously with "complex spine surgery". Some authors define complex procedures based on the surgical approach or fusion on more than two disk levels [14]. In other studies, multilevel thoracolumbar procedures with instrumentation and fusion qualify as "complex spine surgery" [5]. In the present study, the median number of instrumented levels was 10 and a considerable number of patients underwent pedicle subtraction osteotomy. We find that this reflects the complexity of the procedures and therefore, qualifies as "major spine surgery".

The terms "mobilization" and "discharge criteria" are poorly defined in the literature on spine surgery. Although length of hospital stay is often used as an outcome variable, the criteria are not always described in detail or standardized [15]. Other studies use mobilization criteria corresponding to the ones used in the present study requiring the patients to be able to transfer and ambulate before discharge [16]. This corresponds to the criteria used in the assessment of fast-track surgery in hip and knee replacement [17]. Since postoperative mobilization and LOS are closely related parameters, we suggest that a detailed description of discharge criteria is required in future studies including these outcome variables to allow comparison of results reported in the literature.

Other studies have focused on pain management related to spinal surgery. This includes the beneficial effect of epidural steroid after lumbar discectomy [18] and from locally applied methylprednisolone in patients undergoing mixed lumbar surgical interventions [19]. The efficacy of glucocorticoids as part of multimodal postoperative pain treatment in different surgical procedures has recently been reviewed [20] demonstrating reductions in both pain scores and morphine consumption. Likewise, Lunn et al. [21] showed that IV methylprednisolone 125 mg after total knee arthroplasty improved analgesia and promoted recovery. Neither of the studies reported on serious complications, especially wound infection, from the use of a single dose of glucocorticoids, but calls for further largescale studies on safety issues.

The employment of NSAIDs in a surgical population with a high risk of developing pseudoarthrosis can be questioned as it is speculated that NSAIDs may impair bone formation [22]. The debate is ongoing, but it has recently been demonstrated that ketorolac did not predispose to pseudoarthrosis in an adolescent idiopathic scoliosis surgical population [23]. Likewise, Dodwell et al. [24] reviewed NSAID for postoperative pain treatment in seven high-quality retrospective studies in spine surgery and did not find an increased risk of pseudoarthrosis from shortterm NSAID use during a 12-month follow-up period. On the other hand, NSAIDs have demonstrated significant analgesic properties with reduced need of opioids followed by reduced levels of PONV [25]. Thus, we included treatment with ibuprofen until discharge as part of the standard treatment protocol. One year follow-up revealed a similar incidence of re-operation for pseudoarthrosis in the two groups, and no increase in postoperative hematoma in the post-intervention group.

This study has several limitations. First, it is not a randomized blinded trial, which may introduce bias, especially with the historic nature of the data in the control group. However, both the pre- and post-intervention data were collected at well-defined time periods, where the surgical treatment principles and discharge criteria in the department did not change. Second, inconsistency of data is of great concern as most data were tracked from patient and nurse records and especially, data on pain and side-effects in the pre-intervention group was scarce. Therefore, we only have pain and side-effect data in the post-intervention group. Third, the calculation of a morphine equivalent parameter from different opiates with different pharmacokinetic and pharmacodynamic profiles may be questioned. Fourth, comparison of opioid consumption on POD 1 and 2 was only done in patients without a PCA device because of lack of data from this device. This reduces our number of patients on these days and may result in wide IQRs. Fifth, we do not have information on pre-operative pain scores and mobility of the two study groups and therefore cannot tell if the groups were comparable on these points. However, based on the pre-operative SF-36 scores, the healthrelated quality of life was equally affected in the two groups. Sixth, some patients in the pre-intervention group lacked data after discharge or transfer on when they stopped using a walking frame, causing uncertainty on this point.

Overall, this non-randomized and non-blinded study serves as a hypothesis-generating pragmatic description of the results from the implementation of a comprehensive treatment protocol in a population representing a daily clinical challenge and may serve as an inspiration for further investigation in this population. Such studies are warranted since a future increase in complex spine surgery is likely, challenging the request for treatment modalities that can decrease perioperative morbidities like immobilization and pain.

Conclusion

In this study of patients scheduled for multilevel spine surgery, it was demonstrated that compared to a historic group of patients receiving usual care, a comprehensive and standardized multimodal pain and PONV protocol significantly reduced opioid consumption, improved postoperative mobilization and presented concomitant low levels of nausea, sedation and dizziness. The study may serve as inspiration for future randomized studies in this population.

Conflict of interest Benny Dahl is funded by a grant from the Danish Strategic Research Council (#2142-08-0017). No other funding was received for the study.

References

- Pumberger M, Chiu YL, Ma Y et al (2012) National in-hospital morbidity and mortality trends after lumbar fusion surgery between 1998 and 2008. J Bone Joint Surg Br 94:359–364
- Rajaee SS, Bae HW, Kanim LE et al (2012) Spinal fusion in the United States: analysis of trends from 1998 to 2008. Spine (Phila Pa 1976) 37:67–76
- Buvanendran A, Thillainathan V (2010) Preoperative and postoperative anesthetic and analgesic techniques for minimally invasive surgery of the spine. Spine (Phila Pa 1976) 35:S274– S280
- Gottschalk A, Freitag M, Tank S et al (2004) Quality of postoperative pain using an intraoperatively placed epidural catheter after major lumbar spinal surgery. Anesthesiology 101:175–180
- Gottschalk A, Durieux ME, Nemergut EC (2011) Intraoperative methadone improves postoperative pain control in patients undergoing complex spine surgery. Anesth Analg 112:218–223

- Loftus RW, Yeager MP, Clark JA et al (2010) Intraoperative ketamine reduces perioperative opiate consumption in opiatedependent patients with chronic back pain undergoing back surgery. Anesthesiology 113:639–646
- Kehlet H, Dahl JB (1993) The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg 77:1048–1056
- White PF, Kehlet H (2010) Improving postoperative pain management: what are the unresolved issues? Anesthesiology 112: 220–225
- 9. Kehlet H (2005) Postoperative opioid sparing to hasten recovery: what are the issues? Anesthesiology 102:1083–1085
- Kim JC, Choi YS, Kim KN et al (2011) Effective dose of perioperative oral pregabalin as an adjunct to multimodal analgesic regimen in lumbar spinal fusion surgery. Spine (Phila Pa 1976) 36:428–433
- Ziegeler S, Fritsch E, Bauer C et al (2008) Therapeutic effect of intrathecal morphine after posterior lumbar interbody fusion surgery: a prospective, double-blind, randomized study. Spine (Phila Pa 1976) 33:2379–2386
- Nielsen PR, Jorgensen LD, Dahl B et al (2010) Prehabilitation and early rehabilitation after spinal surgery: randomized clinical trial. Clin Rehabil 24:137–148
- Julious SA, George S, Campbell MJ (1995) Sample sizes for studies using the short form 36 (SF-36). J Epidemiol Community Health 49:642–644
- Deyo RA, Mirza SK, Martin BI et al (2010) Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. JAMA 303:1259–1265
- Blumenthal S, McAfee PC, Guyer RD et al (2005) A prospective, randomized, multicenter Food and Drug Administration investigational device exemptions study of lumbar total disc replacement with the CHARITE artificial disc versus lumbar fusion: part I: evaluation of clinical outcomes. Spine (Phila Pa 1976) 30:1565–1575
- 16. Zigler J, Delamarter R, Spivak JM et al (2007) Results of the prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement versus circumferential fusion for the treatment of 1-level degenerative disc disease. Spine (Phila Pa 1976) 32:1155–1162
- Husted H, Holm G, Jacobsen S (2008) Predictors of length of stay and patient satisfaction after hip and knee replacement surgery: fast-track experience in 712 patients. Acta Orthop 79: 168–173
- Rasmussen S, Krum-Moller DS, Lauridsen LR et al (2008) Epidural steroid following discectomy for herniated lumbar disc reduces neurological impairment and enhances recovery: a randomized study with two-year follow-up. Spine (Phila Pa 1976) 33:2028–2033
- Jirarattanaphochai K, Jung S, Thienthong S et al (2007) Peridural methylprednisolone and wound infiltration with bupivacaine for postoperative pain control after posterior lumbar spine surgery: a randomized double-blinded placebo-controlled trial. Spine (Phila Pa 1976) 32:609–616
- De Oliveira GSJ, Almeida MD, Benzon HT et al (2011) Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology 115:575–588
- Lunn TH, Kristensen BB, Andersen LO et al (2011) Effect of high-dose preoperative methylprednisolone on pain and recovery after total knee arthroplasty: a randomized, placebo-controlled trial. Br J Anaesth 106:230–238
- Dahners LE, Mullis BH (2004) Effects of nonsteroidal antiinflammatory drugs on bone formation and soft-tissue healing. J Am Acad Orthop Surg 12:139–143

- 23. Sucato DJ, Lovejoy JF, Agrawal S et al (2008) Postoperative ketorolac does not predispose to pseudoarthrosis following posterior spinal fusion and instrumentation for adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 33:1119–1124
- 24. Dodwell ER, Latorre JG, Parisini E et al (2010) NSAID exposure and risk of nonunion: a meta-analysis of case-control and cohort studies. Calcif Tissue Int 87:193–202
- 25. Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N (2011) Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine related side-effects after major surgery: a systematic review. Br J Anaesth 106:292–297